Seroatlas · Human Serome Atlas

NRAS

GTPase NRas

Also known as: N-ras, RASN_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P01111
Gene
NRAS
Ensembl
ENSG00000213281
Chromosome
1
Canonical length
189 aa
Protein class
Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins
Subcellular location
Plasma membrane,Cytosol

OverviewNCBI Gene

This is an N-ras oncogene encoding a membrane protein that shuttles between the Golgi apparatus and the plasma membrane. This shuttling is regulated through palmitoylation and depalmitoylation by the ZDHHC9-GOLGA7 complex. The encoded protein, which has intrinsic GTPase activity, is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase activating protein. Mutations in this gene have been associated with somatic rectal cancer, follicular thyroid cancer, autoimmune lymphoproliferative syndrome, Noonan syndrome, and juvenile myelomonocytic leukemia. [provided by RefSeq, Jun 2011]

Canonical amino-acid sequenceUniProt

189 residues, UniProt reviewed canonical sequence.

>P01111|NRAS
     1  MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG
    61  QEEYSAMRDQ YMRTGEGFLC VFAINNSKSF ADINLYREQI KRVKDSDDVP MVLVGNKCDL
   121  PTRTVDTKQA HELAKSYGIP FIETSAKTRQ GVEDAFYTLV REIRQYRMKK LNSSDDGTQG
   181  CMGLPCVVM

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NRAS can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.29
Highest tissue expression
55 nTPM

Expression across tissuesHPA

Tissue

  • bone marrow: 55 nTPM
  • thymus: 36 nTPM
  • lymph node: 29 nTPM
  • tonsil: 28 nTPM
  • placenta: 27 nTPM
  • colon: 26 nTPM

Single-cell type

  • esophageal apical cells: 87 nCPM
  • extravillous trophoblasts: 71 nCPM
  • hofbauer cells: 67 nCPM
  • kupffer cells: 66 nCPM
  • gastric progenitor cells: 65 nCPM
  • parietal cells: 53 nCPM

Immune cell

  • basophil: 39 nTPM
  • intermediate monocyte: 19 nTPM
  • non-classical monocyte: 18 nTPM
  • NK-cell: 16 nTPM
  • T-reg: 13 nTPM
  • total PBMC: 13 nTPM

Brain region

  • white matter: 21 nTPM
  • medulla oblongata: 20 nTPM
  • pons: 19 nTPM
  • hypothalamus: 19 nTPM
  • midbrain: 19 nTPM
  • spinal cord: 18 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about NRAS.

Disease | AllUniProt

Conditions NRAS is implicated in, by any mechanism.

  • Leukemia, juvenile myelomonocytic (JMML) MIM:607785
  • Noonan syndrome 6 (NS6) MIM:613224
  • RAS-associated autoimmune leukoproliferative disorder (RALD) MIM:614470
  • Melanocytic nevus syndrome, congenital (CMNS) MIM:137550
  • Melanosis, neurocutaneous (NCMS) MIM:249400
  • Keratinocytic non-epidermolytic nevus (KNEN) MIM:162900
  • Thyroid cancer, non-medullary, 2 (NMTC2) MIM:188470

Disease | GeneticClinVar

26 pathogenic / likely-pathogenic of 348 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | ImmuneIEDB

Conditions an epitope on NRAS was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.61
gnomAD pLI
0.49
gnomAD missense Z
1.71
DepMap mean gene effect
-0.27
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of NRAS in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NRAS as an antibody target. Whether an autoantibody or antibody against NRAS could matter depends on whether native NRAS is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NRAS is annotated at the cell surface, where native NRAS is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Source-annotated serology context

The source annotations explicitly mention antibody, autoantibody, autoantigen, or autoimmune context. This is biological context, not study-specific reactivity.

  • Mutations in this gene have been associated with somatic rectal cancer, follicular thyroid cancer, autoimmune lymphoproliferative syndrome, Noonan syndrome, and juvenile myelomonocytic leukemia.

Canonical record: https://seroatlas.com/gene/NRAS. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...